Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | FLT4 | P35916 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481386 | 1.00 | RET (0.55) | RETEGFRKDRERBB2MAOB | |
| SCHEMBL12303612 | 0.87 | EGFR (0.53) | RETEGFRKDRERBB2CSF1R | |
| SCHEMBL2453432 | 0.87 | EGFR (0.53) | RETEGFRKDRERBB2CSF1R | |
| SCHEMBL2453435 | 0.87 | EGFR (0.53) | RETEGFRKDRERBB2CSF1R | |
| SCHEMBL5487853 | 0.86 | EGFR (0.62) | RETEGFRKDRERBB2 | |
| SCHEMBL2451414 | 0.86 | EGFR (0.58) | RETEGFRKDRERBB2MAOB | |
| SCHEMBL2451417 | 0.86 | EGFR (0.58) | RETEGFRKDRERBB2MAOB | |
| SCHEMBL12303599 | 0.86 | EGFR (0.58) | RETEGFRKDRERBB2MAOB | |
| SCHEMBL12303606 | 0.86 | EGFR (0.62) | RETEGFRKDRERBB2 | |
| SCHEMBL5487850 | 0.86 | EGFR (0.62) | RETEGFRKDRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254896-A1 | SUBSTITUTED PYRIMIDINE KINASE INHIBITORS | DTYMK, TK1, DCK | RET 577/4885EGFR 1449/4885KDR 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.